Lyme disease vaccine - GlaxoSmithKline

Drug Profile

Lyme disease vaccine - GlaxoSmithKline

Alternative Names: LYMErix

Latest Information Update: 03 May 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source; Yale University
  • Developer Nonindustrial source
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Lyme disease

Most Recent Events

  • 03 May 2002 A post-licensure study of adverse events has been added to the adverse events section
  • 04 Mar 2002 Discontinued - Phase-I for Lyme disease in Belgium (Parenteral,Injection)
  • 04 Mar 2002 Discontinued - Phase-II for Lyme disease in Europe (Parenteral,Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top